U.S. Markets open in 6 hrs 25 mins

Today's Research Reports on Hemostemix, TSO3, Emerald Health Therapeutics and DiaMedica Therapeutics

NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Hemostemix Inc.
https://rdinvesting.com/news/?ticker=HEM.V

TSO3 Inc.
https://rdinvesting.com/news/?ticker=TOS.TO

Emerald Health Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=EMH.V

DiaMedica Therapeutics Inc.
https://rdinvesting.com/news/?ticker=DMA.V

Hemostemix’s stock dropped 5.26% on Monday, to close the day at $0.09. The stock recorded a trading volume of 134,000 shares, which was below its three months average volume of 221,632 shares. In the last year, Hemostemix's shares have traded in a range of 0.05 - 0.14. The share price has gained 80% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.08 is greater than its 200-day moving average of $0.07. Shares of Hemostemix have gained approximately 28.57 percent year-to-date.

Access RDI's Hemostemix Inc. Research Report at:
https://rdinvesting.com/news/?ticker=HEM.V

On Monday, shares of TSO3 recorded a trading volume of 125,970 shares, which was above the three months average volume of 95,075 shares. The stock ended the day flat at $0.61. The share price has fallen 78.6% from its 52 week high with a 52 week trading range of 0.56 - 2.85. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.68 is lower than its 200-day moving average of $0.88. Shares of TSO3 have fallen approximately 76.63 percent year-to-date.

Access RDI's TSO3 Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TOS.TO

Emerald Health Therapeutics’ stock jumped 3.37% Monday, to close the day at $5.21. The stock recorded a trading volume of 750,017 shares, which was below its three months average volume of 1,310,724 shares. In the last year, Emerald Health Therapeutics, Inc.'s shares have traded in a range of 1.20 - 9.68. The share price has gained 334.17% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.86 is lower than its 200-day moving average of $4.24.

Access RDI's Emerald Health Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EMH.V

On Monday, shares of DiaMedica Therapeutics recorded a trading volume of 140,300 shares, which was below the three months average volume of 230,172 shares. The stock ended the day flat at $0.485. The share price has fallen 46.11% from its 52 week high with a 52 week trading range of 0.21 - 0.90. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.529 is lower than its 200-day moving average of $0.554. Shares of DiaMedica Therapeutics have gained approximately 68.97 percent year-to-date.

Access RDI's DiaMedica Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=DMA.V

Our Actionable Research on Hemostemix Inc. (TSX-V: HEM.V), TSO3 Inc. (TSX: TOS.TO), Emerald Health Therapeutics, Inc. (TSX-V: EMH.V) and DiaMedica Therapeutics Inc. (TSX-V: DMA.V) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

https://www.accesswire.com/512115/Todays-Research-Reports-on-Hemostemix-TSO3-Emerald-Health-Therapeutics-and-DiaMedica-Therapeutics